Abstract:Sphingolipids play a very important role in cell membrane formation, signal transduction, and plasma lipoprotein metabolism, and all these functions may have an impact on atherosclerotic development. Serine palmitoyl-CoA transferase (SPT) is the key enzyme in sphingolipid biosynthesis. To evaluate in vivo SPT activity and its role in sphingolipid metabolism, we applied homologous recombination to embryonic stem cells, producing mice with long chain base 1 (Sptlc1) and long chain base 2 (Sptlc2), two subunits of SPT, gene deficiency. Homozygous Sptlc11 and Sptlc2 mice are embryonic lethal, whereas heterozygous versions of both animals (Sptlc1+/−, Sptlc2+/−) are healthy. Analysis showed that, compared with WT mice, Sptlc1+/− and Sptlc2+/− mice had: (1) decreased liver Sptlc1 and Sptlc2 mRNA by 44% and 57% (P<0.01 and P<0.0001, respectively); (2) decreased liver Sptlc1 mass by 50% and Sptlc2 mass by 70% (P<0.01 and P<0.01, respectively), moreover, Sptlc1 mass decreased by 70% in Sptlc2+/− mouse liver, while Sptlc2 mass decreased by 53% in Sptlc1+/− mouse liver (P<0.001 and P<0.01, respectively); (3) decreased liver SPT activity by 45% and 60% (P<0.01, respectively); (4) decreased liver ceramide (22% and 39%, P<0.05 and P<0.01, respectively) and sphingosine levels (22% and 31%, P<0.05 and P<0.01, respectively); (5) decreased plasma ceramide (45% and 39%, P<0.01, respectively), sphingosine-1-phosphate (31% and 32%, P<0.01, respectively) and sphingosine levels (22.5% and 25%, P<0.01, respectively); (6) dramatically decreased plasma lysosphingomyelin (17-fold and 16-fold, P<0.0001, respectively); and (7) no change of plasma sphingomyelin, triglyceride, total cholesterol, phospholipids, and liver sphingomyelin levels. These results indicated that both Sptlc1 and Sptlc2 interactions are necessary for SPT activity in vivo, and that SPT activity directly influences plasma sphingolipid levels. Furthermore, manipulation of SPT activity might well influence the course of such diseases as atherosclerosis.

A key enzyme in the biogenesis of lysosomes is a protease that regulates cholesterol metabolism

Site-1 protease and lysosomal homeostasis

Impaired regulation of sterol regulatory element binding protein 2 in cholesterol gallstone-susceptible mice.

Saposin A mobilizes lipids from low cholesterol and high bis(monoacylglycerol)phosphate-containing membranes: patient variant Saposin A lacks lipid extraction capacity

Lysosomal integral membrane protein-2 (LIMP-2/SCARB2) is involved in lysosomal cholesterol export

Lack of SPNS1 results in accumulation of lysolipids and lysosomal storage disease in mouse models

Site-1 Protease Deficiency Causes Human Skeletal Dysplasia

SPNS1 is required for the transport of lysosphingolipids and lysoglycerophospholipids from lysosomes

Sphingosine 1-phosphate lyase ablation disrupts presynaptic architecture and function via an ubiquitin- proteasome mediated mechanism

Severe kidney dysfunction in sialidosis mice reveals an essential role for neuraminidase 1 in reabsorption

Structure of a truncated human GlcNAc-1-phosphotransferase variant reveals the basis for its hyperactivity

MFSD12 affects glycosphingolipid metabolism by modulating lysosome homeostasis

Intramembrane protease SPP defines a cholesterol-regulated abundance control of the mevalonate pathway enzyme squalene synthase

A turn in the road: How studies on the pharmacology of glucosylceramide synthase inhibitors led to the identification of a lysosomal phospholipase A2 with ceramide transacylase activity

Serine Palmitoyl-Coa Transferase (SPT) Deficiency and Sphingolipid Levels in Mice.

Spns1 is a lysophospholipid transporter mediating lysosomal phospholipid salvage

Saposin B mobilizes lipids from cholesterol-poor and bis(monoacylglycero)phosphate-rich membranes at acidic pH. Unglycosylated patient variant saposin B lacks lipid-extraction capacity

Prosaposin is cleaved into saposins by multiple cathepsins in a progranulin-regulated fashion

Overexpression of Mouse GlcNAc-1-phosphotransferase-γ Subunit in Cells Induced an I-cell-like Phenotype of Mucolipidosis

Lysosomal diseases: biochemical pathways and investigations

Membrane lipids and their degradation compounds control GM2 catabolism at intralysosomal luminal vesicles